Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 9 January 2018, 20:24 HKT/SGT

Source: Eisai
Biogen and Eisai Commence Co-Promotion of Multiple Sclerosis Treatments in Japan

TOKYO, Jan 9, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd. announced that the companies have commenced co-promotion of Biogen Japan's multiple sclerosis treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of today.

Based on the provisions of the agreement, the two companies will jointly conduct promotional activities at the clinical facilities for which they are responsible and provide information on appropriate use. There will be no change to the manufacturing or logistic systems, and Biogen Japan books sales of the products.

An autoimmune disease of the central nervous system, multiple sclerosis is a serious, chronic, progressive disease accompanied by inflammation. It affects cognitive function, mental and social functions as well as physical functions. With multiple sclerosis, lesions are found widely throughout the central nervous system such as the brain, spinal cord and optic nerves, and depending on where these lesions occur, a diverse range of symptoms appear including visual impairment, impaired movement and sensation, as well as abnormal gait. As such, it can take several years to reach a conclusive diagnosis, and it is a disease with significant unmet medical needs. The incidence of multiple sclerosis in Japan is reported as 10.8 to 14.4 per 100,000.(1)

Eisai Representative Corporate Officer, Japan Business and CIO Hideki Hayashi commented, "Eisai considers neurology a strategic therapeutic area of focus and possesses rich experience and knowledge in neurology products such as Aricept and Fycompa. Leveraging these strengths, we hope to maximize the benefits for multiple sclerosis patients and their families."
Biogen Japan President and Representative Director Shinichi Torii commented, "Biogen is a leading company in multiple sclerosis, and approximately 40% of multiple sclerosis patients worldwide use Biogen's medicines. By co-promoting with Eisai who has strong networks in the field of neurology, we believe we can reliably deliver multiple sclerosis treatments to patients who need them."

About Multiple Sclerosis Treatments TECFIDERA, TYSABRI and AVONEX

TECFIDERA (dimethyl fumarate) is an orally-administered medicine for the treatment of relapsing forms of multiple sclerosis, including relapse-remitting multiple sclerosis, the most common type of multiple sclerosis.

TECFIDERA was approved in Japan for the prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis in December 2016, and was launched in February 2017. First approved in 2013 in the United States, TECFIDERA is currently approved in 54 countries (as of August 2016). TECFIDERA is widely used in the United States and countries in Europe as a first-line treatment, and the number of patients who have been treated with TECFIDERA worldwide to date reached 250,000.

TYSABRI (natalizumab, genetic recombinant) is a humanized monoclonal anti-alpha4 integrin antibody and a disease modifying drug. TYSABRI was approved in Japan for the prevention of relapse and delaying the accumulation of physical disability in multiple sclerosis in March 2014, and was launched in June of the same year. TYSABRI has been approved in over 77 countries worldwide (as of April 2016) including the United States and countries in Europe, and the number of patients who have been treated with TYSABRI worldwide reached 167,000.

AVONEX (interferon beta 1a, genetic recombinant) was approved in Japan for relapse prevention of multiple sclerosis in July 2006, and was launched in November of the same year. In December 2013 a pen formulation was approved and subsequently launched in June 2014.

About Biogen Japan

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.

Founded in 1978 as one of the world's first global biotechnology companies by Charles Weissman and Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer's disease and dementia, neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics. We routinely post information that may be important to investors on our website at To learn more, please visit and follow us on social media - Twitter, LinkedIn, Facebook, YouTube.
Biogen Japan is a subsidiary of Biogen in the U.S. Biogen Japan, as the Japan affiliate of one of the oldest independent biotechnology companies, started its operation in Japan in 2000. To learn more about Biogen Japan, please visit

(1) Kinoshita M, Obata K, Tanaka M. Latitude has more significant impact on prevalence of multiple sclerosis than ultraviolet level or sunshine duration in Japanese population. Neurol Sci. 2015;36(7):1147-51.

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

Public Relations Department,
Eisai Co., Ltd.

Jan 9, 2018 20:24 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Mar 14, 2018 11:16 HKT/SGT
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
Mar 8, 2018 13:33 HKT/SGT
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
Mar 8, 2018 12:00 HKT/SGT
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Feb 27, 2018 09:33 HKT/SGT
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
Feb 21, 2018 08:25 HKT/SGT
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)
Feb 16, 2018 07:34 HKT/SGT
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
Feb 12, 2018 09:03 HKT/SGT
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
Feb 1, 2018 16:20 HKT/SGT
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan
Jan 22, 2018 09:51 HKT/SGT
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)
Jan 20, 2018 18:32 HKT/SGT
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: